

# ZILBRYSQ (zilucoplan) Is Available Exclusively Through a Single Specialty Pharmacy—**PANTHERx Rare**

UCB is committed to helping adult patients access ZILBRYSQ, which is administered at home once daily via subcutaneous self-injection. Prescriptions will be fulfilled exclusively through PANTHERx Rare. ZILBRYSQ is available only through a restricted program called [ZILBRYSQ REMS](#).

Prescriptions can be submitted to PANTHERx Rare through the following options:

ePrescribe	Fax	Phone
NPI #1659762524*	412-567-6135	833-418-7760

\*Use this NPI number when submitting a prescription electronically to PANTHERx Rare.

**For more information, visit [pantherxrare.com](http://pantherxrare.com) or call 833-418-7760**

## INDICATION

ZILBRYSQ (zilucoplan) is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

## IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING

### WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

ZILBRYSQ, a complement inhibitor, increases the risk of serious infections caused by *Neisseria meningitidis*. Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.

- Complete or update vaccination for meningococcal bacteria at least 2 weeks prior to the first dose of ZILBRYSQ, unless the risks of delaying therapy outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccination against meningococcal bacteria in patients receiving a complement inhibitor.
- Patients receiving ZILBRYSQ are at increased risk for invasive disease caused by *Neisseria meningitidis*, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious meningococcal infections and evaluate immediately if infection is suspected.

ZILBRYSQ is available only through a restricted program called ZILBRYSQ REMS.

NPI=National Provider Identifier; REMS=Risk Evaluation and Mitigation Strategy.

**Please refer to the next page for additional Important Safety Information.**

**Please refer to the full Prescribing Information, including Boxed Warning for serious meningococcal infections, provided by the UCB representative and visit [ZILBRYSQhcp.com](http://ZILBRYSQhcp.com).**

**IMPORTANT SAFETY INFORMATION (cont'd)**

**CONTRAINDICATIONS**

ZILBRYSQ is contraindicated for initiation in patients with unresolved serious *Neisseria meningitidis* infection.

**WARNINGS AND PRECAUTIONS**

**Other Infections**

Use caution when administering ZILBRYSQ to patients with any other systemic infection.

**Pancreatitis and Other Pancreatic Conditions**

Pancreatitis and pancreatic cysts have been reported in patients treated with ZILBRYSQ. Discontinue ZILBRYSQ in patients with suspected pancreatitis and initiate appropriate management until pancreatitis is ruled out or has resolved.

**ADVERSE REACTIONS**

The most common adverse reactions ( $\geq 10\%$ ) were injection site reactions, upper respiratory tract infections, and diarrhea.

**Please refer to the full Prescribing Information, including Boxed Warning for serious meningococcal infections, provided by the UCB representative and visit [ZILBRYSQhcp.com](https://www.zilbrysqhcp.com).**

**For more information about ZILBRYSQ, visit [ZILBRYSQhcp.com](https://www.zilbrysqhcp.com).**

**For additional information, contact UCB Cares<sup>®</sup> at 1-844-599-CARE (2273).**

**Reference:** ZILBRYSQ [prescribing information]: Smyrna, GA: UCB, Inc.



ZILBRYSQ<sup>®</sup> and UCB Cares<sup>®</sup> are registered trademarks of the UCB Group of Companies.  
All other trademarks are the property of their respective holders.  
©2025 UCB, Inc., Smyrna, GA 30080. All rights reserved.  
US-ZL-2500139 | March 2025